GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Clinical Oncology (ASCO)  (4)
  • 1
    Online Resource
    Online Resource
    Quantification of timeloss within complex tumor therapies.
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  JCO Global Oncology Vol. 9, No. Supplement_1 ( 2023-08), p. 126-126
    Details
    In: JCO Global Oncology, American Society of Clinical Oncology (ASCO), Vol. 9, No. Supplement_1 ( 2023-08), p. 126-126
    Abstract: 126 Background: There are various studies on reducing the waiting time of tumor patients before therapy sessions. In this study, we investigated how much waiting time within therapy sessions occurs due to delayed administration of the next drug. In addition, digital documented infusion time of specific drugs were determined to calculate waiting time. Both metrics serve as an indication of the potential to improve the effectiveness and efficiency of the infusion process. Methods: The therapy sequence of preliminary 29 patients in the Outpatient Therapy Center of the University Hospital Dresden was investigated. PDF export of the prescriptions of all cycles of the patient with the documentation of the therapy sequences from BD Cato is performed. In python the extraction of all time stamps and the processing of all start and stop times of the medication administration took place. Based on this data, waiting time between infusions were calculated. In addition, analysis of the total administration time of the specific medication was performed. Results: This revealed a median of 23 minutes of patient waiting time between infusion sequences (n = 29 patients and 1154 measured infusion changes). We compared 7 specific medications to the intended infusion time, taking particular note of the high variance in duration. We postulate due to standard administration protocols that the infusion time variance indicates additional waiting time. Both metrics are only an indication, since other factors besides the waiting time can also influence the time between two infusions. Conclusions: Treatment time for the same therapy protocol varied widely between patients, both in terms of waiting time between infusions and in the duration of infusion compared to the intended infusion time. Both indicate the opportunity to improve efficiency, thus providing more hospital-free lifetime for patients and increase revenue and standardization for treatment centers.
    Type of Medium: Online Resource
    ISSN: 2687-8941
    URL: Article
    DOI: 10.1200/GO.2023.9.Supplement_1.126
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 3018917-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Do external factors such as weather affect patient reported outcomes of patients with malignant diseases?
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. e18715-e18715
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e18715-e18715
    Abstract: e18715 Background: The QLQ-C30 is one of the most widely used patient-reported outcome (PRO) instrument to assess health-related quality of life in cancer patients developed by the European Organization for Research and Treatment of Cancer (EORTC). Even if only little scientific evidence is published on this topic, patients often report that their emotional and physical state varies depending on climatic conditions. To enhance the understanding of quality of life in cancer patients, this study analyzed whether external factors like weather data and season can influence PRO measures and cancer patients’ well-being. Methods: Over a period of 12 months data was obtained from inpatient and outpatient cancer patients in two German cancer centers using the QLQ-C30. Items were assigned to five functional scales, three symptom scales, a global health status/QoL scale, and a number of single items assessing symptoms commonly reported by cancer patients.Patients were approached by their medical oncologist or nursing staff to complete the questionnaire anonymously once or multiple times. QoL data were linked to weather factors including temperature, hours of sunshine and season. Results: We received a total of n = 5040 responses (54 % male). Regarding global health status/QoL, the best result was recorded at 25 - 30 degrees, and the lowest value was measured at 5 - 10 degrees (mean 61.3 vs. 52.6, p 〈 0.001). Insomnia was most pronounced at 〈 = 0 degrees and least present at 25 – 30 degrees (mean 39.3 vs. 29.5, p 〈 0.001). Overall, best scores were obtained at 25 – 30 degrees, whereas quality of life and symptom burden were worst at 5 – 10 degrees. Global health/QoL was highest at 8 hours of sunshine and lowest at 0 hours of sunshine (mean 56.9 vs. 50.9, p .003). Global health/QoL was lower in winter months than in summer (mean 53.8 vs. 57.4, p 〈 0.001) presenting highest scores in June and July. Conclusions: The findings of our study indicate that quality of life in cancer patients as well as PROs can be influenced systematically by external factors like season or weather conditions. This could possibly also be of importance when interpreting the results of studies that use standardized instruments to assess health-related quality of life in cancer patients -e.g., if the questionnaires were only answered in certain month (summer/winter) or under external conditions that were not evenly distributed.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2023.41.16_suppl.e18715
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
    American Society of Clinical Oncology (ASCO) ; 2006
    In:  Journal of Clinical Oncology Vol. 24, No. 36 ( 2006-12-20), p. 5664-5671
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 24, No. 36 ( 2006-12-20), p. 5664-5671
    Abstract: The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer. Patients and Methods Between June 1997 and March 2000, 1,999 patients with operable node-positive breast cancer were randomly assigned to either FEC every 21 days for six cycles, or three cycles of FEC followed by three cycles of docetaxel, both given every 21 days. Hormone-receptor–positive patients received tamoxifen for 5 years after chemotherapy. The primary end point was 5-year disease-free survival (DFS). Results Median follow-up was 60 months. Five-year DFS rates were 73.2% with FEC and 78.4% with FEC-D (unadjusted P = .011; adjusted P = .012). Multivariate analysis adjusted for prognostic factors showed an 18% reduction in the relative risk of relapse with FEC-D. Five-year overall survival rates were 86.7% with FEC and 90.7% with FEC-D, demonstrating a 27% reduction in the relative risk of death (unadjusted P = .014; adjusted P = .017). The incidence of grade 3 to 4 neutropenia, the need for hematopoietic growth factor, and incidence of nausea/vomiting were higher with FEC. Docetaxel was associated with more febrile neutropenia in the fourth cycle, stomatitis, edema, and nail disorders. Though rare overall, there were fewer cardiac events after FEC-D (P = .03), attributable mainly to the lower anthracycline cumulative dose. Conclusion Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2006.07.3916
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2006
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients: Impact on survival and resection rates.
    American Society of Clinical Oncology (ASCO) ; 2017
    In:  Journal of Clinical Oncology Vol. 35, No. 15_suppl ( 2017-05-20), p. e15029-e15029
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e15029-e15029
    Abstract: e15029 Background: Initially unresectable colorectal liver metastases can become resectable after chemotherapy. Chemotherapy combined with EGF-receptor antibodies has shown consistent high response rates in patients with RAS wildtype tumors. However, the influence of RAS mutations other than exon 2 mutations in the context of a conversion strategy has not been systematically studied yet. Methods: Out of a cohort of 424 patients with mCRC, we identified 30 patients with initially unresectable KRAS exon 2 wildtype colorectal liver metastases who received neoadjuvant chemotherapy including cetuximab or panitumumab between January 2008 and February 2014. In all patients extended RAS analysis (KRAS and NRAS exon 3 codon 59 and 61 and exon 4 codon 117 and 146) was carried out. Resection status (R0, R1 or R2), PFS and OS were recorded in all patients and maximum tumor shrinkage was calculated. Results: RAS mutation analysis identified further KRAS mutations in 4/30 patients (13.3%). No NRAS mutations were found. In none of these four patients a R0 resection could be achieved. In contrast, 15/26 (57.7%) RAS wildtype patients could be R0 resected. Median survival of patients with a RAS wildtype tumor was 64.0 [range: 7.4-98.6] months vs. 28.0 [range: 16.4- 40.6] months in those with a RAS mutation (hazard ratio, HR, 0.53; 95% confidence interval, CI: 0.15-1.81, p = 0.3). Median PFS in patients with a RAS mutation was 8 [range: 6-28.8] months compared to 10.4 [range, 1.7-15.2] months in patients with a RAS wildtype cancer. Median overall survival was 〉 63.3 months in R0-resected patients vs. 30.0 months in those with a R1 or R2 resection (HR 0.23; [95% CI 0.10- 0.75; p = 0.008). Conclusions: Our data suggest that a RAS wildtype status and a R0 resection are the strongest predictors for overall survival. The extended RAS analysis allows a better patient selection for anti-EGFRbased conversion chemotherapy before secondary resection of colorectal liver metastases.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2017.35.15_suppl.e15029
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...